title: Acute myeloblastic leukemia.
abstract: Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating agent approved for the treatment of patients with MDS, including AML with 20% to 30% bone marrow blasts, according to World Health Organization classification. The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where MDS transformed to AML.
authors: Department of Hematology, Hospital Universitario San Agustín, Linares, Jaén, Spain.
authors: Carmen Avellaneda
authors: CA
authors: Molina
authors: Maria José Requena
authors: MJ
authors: Rodríguez
authors: Nieves Somolinos
authors: NS
authors: de Marcos
authors: Patricia
authors: P
authors: Font
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology; D004893:Erythema Nodosum / Q000209:etiology; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008172:Lung Diseases, Fungal / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D012074:Remission Induction
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine